Facts
- HQ
- Boston, MA, US
- Sectors
- Investment Management
- Founded
- 2023
- Employees
- 3
Oak Hill Bio to Merge with RACC in Deal Delivering ~$175M to Advance Rugonersen; Nasdaq Ticker OAKH, Close Expected by Year-End 2026
Oak Hill Bio and SPAC Research Alliance Corporation III (RACC) agreed to a business combination that will provide approximately $175 million in gross proceeds (including $75 million in RACC trust cash backed by RA Capital and $100 million committed private financing) to advance rugonersen, an antisense oligonucleotide for Angelman syndrome, with the combined company expected to list on Nasdaq as OAKH and close by year-end 2026. The financing plus Oak Hill Bio’s recent $32.5 million Series A is intended to fund development through a Phase 3 readout and potential NDA submission in the second half of 2029.
